Obgyn: Ovarian Cancer: Free MSRA Podcast

🎧 FREE MSRA PODCAST – Ovarian Cancer: From Vague Symptoms to Vital SignsFacing vague symptoms? Ovarian cancer is the leading cause of gynae cancer deaths in the UK – but early recognition changes everything. This deep dive gives you the absolute high-yield facts and essential UK NICE exam insights to boost your MSRA revision and clinical confidence.📝 Key Learning Points📌 Definition & Types• Ovarian cancer = malignant tumour of the ovary, often epithelial (90% – mainly serous type), but also includes germ cell & sex cord-stromal tumours• Most common after menopause; high-grade serous carcinoma = most aggressive📌 Causes & Risk Factors• Genetics: BRCA1/2 mutations, Lynch syndrome• Family history of ovarian/breast/colorectal cancer• Reproductive factors: early menarche, late menopause, nulliparity, infertility• Others: age >50, HRT, endometriosis, obesity, smoking• Protective: pregnancy, breastfeeding, OCP use, tubal ligation, hysterectomy📌 Symptoms• Often vague & non-specific: – Bloating – Pelvic/abdominal pain – Early satiety – Urinary frequency/urgency• Red flag: persistent or frequent symptoms, especially in women >50• Late features: ascites, weight loss, abnormal bleeding, pleural effusion, bowel obstruction📌 Investigations & Diagnosis (UK Pathway)• Primary care: – CA-125 blood test (≥35 IU/mL triggers further investigation) – Urgent pelvic ultrasound if CA-125 raised• Secondary care: – CT abdomen/pelvis, chest – Risk of Malignancy Index (RMI): >250 (NICE) = MDT referral – AFP & β-hCG for germ cell tumours in women <40• Definitive: biopsy at surgery/laparoscopy• No population screening available📌 Management• MDT approach: – Surgery (debulking, staging, oophorectomy, hysterectomy, omentectomy, lymph nodes) – Platinum-based chemotherapy (carboplatin + paclitaxel) – Targeted therapies: PARP inhibitors (BRCA+), bevacizumab (anti-VEGF)• Follow-up: CA-125 for monitoring, regular imaging• Genetic counselling for all diagnosed patients📌 Complications• Tumour-related: torsion, rupture, infection• Advanced disease: bowel obstruction, ascites, pleural effusion, malnutrition, infection• Treatment-related: bone marrow suppression, neuropathy, nephrotoxicity, ototoxicity• Recurrence common (75% relapse rate), palliative care often needed📌 Prognosis• Stage at diagnosis is key – Stage 1: >90% 5-year survival – Overall: ~46% 5-year survival (due to 80% presenting at advanced stages)• Mortality falling in the UK – early recognition saves lives📎 More Ovarian Cancer Revision Resources:📝 Revision Notes: https://www.passthemsra.com/topic/ovarian-cancer-revision-notes/💬 Accordion Q&A: https://www.passthemsra.com/topic/ovarian-cancer-accordion-qa-notes/🧠 Flashcards: https://www.passthemsra.com/topic/ovarian-cancer-flashcards/🚀 Rapid Quiz: https://www.passthemsra.com/topic/ovarian-cancer-rapid-quiz/🧪 Quiz Bank: https://www.passthemsra.com/quizzes/ovarian-cancer/🎓 Full Course: https://www.passthemsra.com/courses/obstetrics-and-gynaecology-for-the-msra/#MSRA #OvarianCancer #MSRARevision #GynaeOncology #PassTheMSRA #HighYield #ExamRevision #UKGuidelines #Gynaecology #ObstetricsAndGynaecology